Compound Reference

Tirzepatide

Dual GIP + GLP-1 receptor agonist ("twincretin") · marketed as Mounjaro / Zepbound

Metabolic · dual incretinEvidence: large Phase 3 RCTsFDA-approved drug

Important distinction. Tirzepatide is an FDA-approved prescription drug, not a research chemical. This is educational science, not medical advice, and not an endorsement of sourcing it outside a licensed prescription.

What it is

Tirzepatide is a single engineered peptide that activates two incretin receptors at once — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 — earning the nickname "twincretin." It builds on the GLP-1 story by adding a second, complementary pathway.

Mechanism of action

Both GIP-R and GLP-1R are class B GPCRs.² Agonizing both is thought to produce additive/synergistic effects on insulin secretion, glucagon, gastric emptying, and appetite — which is the leading explanation for why tirzepatide has shown greater weight and glycemic effects than GLP-1 alone in head-to-head trials.¹ The precise contribution of GIP-agonism is still an active research question.

Why it matters: tirzepatide is the proof-of-concept that multi-receptor peptides can outperform single-target ones — the design logic now driving triple agonists like retatrutide.

Pharmacokinetics

Class	Dual GIP/GLP-1 receptor agonist
Modification	C20 fatty-diacid acylation + albumin binding + DPP-4-resistant residues
Half-life	≈ 5 days (once-weekly)
Receptors	GIP-R and GLP-1R (class B GPCRs)

Same half-life-engineering toolkit as semaglutide — a fatty-acid chain enabling albumin binding turns a short-lived peptide into a weekly drug.³

State of the evidence

Large Phase 3 base: the SURPASS program (type 2 diabetes) and SURMOUNT program (obesity), with cardiovascular and other outcomes trials ongoing. This is a top-evidence-tier, FDA-approved drug — the opposite of an RUO peptide with no trials.

Regulatory reality

Approved: FDA-approved (Mounjaro/Zepbound), prescription-only.
Compounded "research" tirzepatide: the FDA has moved to exclude tirzepatide from the 503B bulks list; the shortage-era compounding window has closed.⁴ Powder sold as a chemical is not the approved medicine.

References

Investigational GLP-1-based medicines & triple-targeting (Harvard HMS insight). learn.hms.harvard.edu
Kobilka, GPCR structure (2012 Nobel lecture/review). Angew. Chem.
Peptide half-life extension — lipidation/albumin binding (review). ACS Med. Chem. Lett.
FDA: proposal to exclude semaglutide/tirzepatide/liraglutide from 503B bulks list. fda.gov

Explore the full library & 75-compound reference →

For educational and research purposes only. This content is not medical advice. Tirzepatide is a prescription drug; obtain and use medicines only under a licensed professional. Free Peptide University does not sell compounds.